ment of Veterans Affairs, the Department of Defense, and 
the Centers for Medicare & Medicaid Services), private 
vendors, health care organizations, pharmacy benefit man-
agers, and other entities as appropriate to obtain reliable 
and comparable human antimicrobial drug consumption 
data (including, as available and appropriate, volume anti-
microbial distribution data and antimicrobial use data, in-
cluding prescription data) by State or metropolitan areas. 
‘‘(c) ANTIMICROBIAL RESISTANCE TREND DATA.— 
The Secretary shall intensify and expand efforts to collect 
antimicrobial resistance data and encourage adoption of 
the antimicrobial resistance and use module within the 
National Healthcare Safety Network among all health 
care facilities across the continuum of care, including, as 
appropriate, acute care hospitals, dialysis facilities, nurs-
ing homes, ambulatory surgical centers, and other ambula-
tory health care settings in which antimicrobial medica-
tions are routinely prescribed. The Secretary shall seek to 
collect such data from electronic medication administra-
tion reports and laboratory systems to produce the reports 
described in subsection (d). 
‘‘(d) PUBLIC AVAILABILITY
OF DATA.—The Sec-
retary shall, for the purposes of improving the monitoring 
of important trends in patient outcomes in relation to 
antimicrobial resistance— 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS
‘‘(1) make the data derived from surveillance 
under this section publicly available through reports 
issued on a regular basis that is not less than annu-
ally; and 
‘‘(2) examine opportunities to make such data 
available in near real time. 
‘‘SEC. 319E–2. DETECTING NETWORK OF ANTIMICROBIAL 
RESISTANCE REGIONAL LABORATORIES. 
‘‘(a) IN GENERAL.—The Secretary shall establish not 
less than 7 Antimicrobial Resistance Surveillance and 
Laboratory Network sites, building upon the intramural 
and extramural programs and laboratories of the Centers 
for Disease Control and Prevention, to intensify, strength-
en, and expand the national capacity to— 
‘‘(1) monitor the emergence and changes in the 
patterns of antimicrobial-resistant pathogens; 
‘‘(2) describe, confirm, and, as necessary, facili-
tate a response to, local or regional outbreaks of re-
sistant pathogens; 
‘‘(3) assess and describe antimicrobial resist-
ance patterns to inform public health and improve 
prevention practices; 
‘‘(4) obtain isolates of pathogens, and in par-
ticular, pathogens that show new or atypical pat-
terns of resistance adversely affecting public health; 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS
‘‘(5) assist in studying the epidemiology of in-
fections from such pathogens; 
‘‘(6) evaluate commonly used antimicrobial sus-
ceptibility testing methods to improve the accuracy 
of resistance testing and reporting; 
‘‘(7) as necessary, develop or evaluate novel di-
agnostic tests capable of detecting new or emerging 
resistance in pathogens; 
‘‘(8) link data generated by regional laboratory 
networks under existing public health surveillance 
networks and relevant government agencies; and 
‘‘(9) provide laboratory assistance and reference 
testing of antimicrobial-resistant pathogens to en-
hance infection control and facilitate outbreak detec-
tion and response in health care and community set-
tings. 
‘‘(b) GEOGRAPHIC DISTRIBUTION.—The sites estab-
lished under subsection (a) shall be geographically distrib-
uted across the United States. 
‘‘(c) NONDUPLICATION OF CURRENT NATIONAL CA-
PACITY.—The sites established under subsection (a) may 
be based in academic centers, health departments, and ex-
isting surveillance and laboratory sites. 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS
‘‘SEC. 
319E–3. 
CLINICAL 
TRIALS 
NETWORK 
ON 
ANTI-
MICROBIAL RESISTANCE. 
‘‘(a) IN GENERAL.—The Secretary shall maintain a 
Clinical Trials Network on Antimicrobial Resistance to en-
hance, strengthen, and expand research on clinical science, 
antimicrobial and diagnostic development, and optimal 
usage strategies with respect to addressing antimicrobial 
resistance. Such Network shall, at a minimum— 
‘‘(1) facilitate research to better understand re-
sistance mechanisms and how to prevent, control, 
and treat resistant organisms; 
‘‘(2) advance clinical trial efforts to develop 
antimicrobial diagnostics, and evaluate and optimize 
the usage of such antimicrobial diagnostics; 
‘‘(3) conduct clinical research to develop natural 
histories of resistant infectious diseases; 
‘‘(4) examine patient outcomes with currently 
available antimicrobial therapy and validate and im-
prove upon biomarkers and other surrogate end-
points; and 
‘‘(5) study shorter treatment duration and early 
cessation of antimicrobial therapy for treatment effi-
cacy and the effect on development of resistance. 
‘‘(b) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS
such sums as may be necessary for each of fiscal years 
2023 through 2029. 
‘‘SEC. 319E–4. REGIONAL PREVENTION COLLABORATIVE EF-
FORTS. 
‘‘(a) IN GENERAL.—The Secretary shall work with 
State and local health departments to support the expan-
sion of collaborative efforts by groups of health care facili-
ties that focus on preventing the spread of antimicrobial- 
resistant pathogens that pose a serious threat to public 
health, and that are designed to interrupt and prevent the 
transmission of significant antimicrobial-resistant patho-
gens being transmitted across health care settings in a ge-
ographic region. Such collaborative efforts shall— 
‘‘(1) identify significant drug resistant patho-
gens being transmitted across health care settings 
locally; 
‘‘(2) implement evidence-based interventions to 
interrupt the transmission of antimicrobial-resistant 
strains of pathogens and prevent the infections 
caused by such pathogens, including evidence-based 
transmission prevention guidelines, rigorous hand- 
hygiene protocols, and infection control and preven-
tion measures; 
‘‘(3) assess compliance and identify barriers to 
adherence to such measures; 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS
‘‘(4) evaluate the impact of such measures, to 
the extent possible, on hospital readmissions in 
health care facilities across the continuum of care, 
rates of health care associated infections, or any 
other relevant measures that characterize the health 
or economic impact of the collaborative efforts; and 
‘‘(5) provide recommendations for improved 
outcomes and compliance with such measures. 
‘‘(b) PREVENTION EPICENTERS.— 
‘‘(1) EXPANSION.—The Secretary may intensify 
and expand academic public health partnerships 
through the Prevention Epicenters Program to pro-
vide the regional prevention collaboration efforts de-
scribed in subsection (a) with tools, strategies, and 
evidence-based interventions. 
‘‘(2) EVALUATIONS AND RESEARCH.—The Di-
rector of the Centers for Disease Control and Pre-
vention and the epicenters participating in the Pre-
vention Epicenters Program shall work with entities, 
including the entities participating in the regional 
prevention collaborative efforts, to— 
‘‘(A) evaluate new and existing interven-
tions to prevent or limit infection rates in 
health care facilities across the continuum of 
care and in community settings; 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS
‘‘(B) facilitate public health research on 
the prevention and control of resistant orga-
nisms; and 
‘‘(C) assess the feasibility, cost-effective-
ness, and appropriateness of surveillance and 
prevention programs in differing health care 
and institutional settings. 
‘‘(c) EDUCATIONAL
MATERIALS.—The Secretary 
shall use the evaluations, research, and assessments de-
scribed in subsection (b), along with other scientific evi-
dence, to create and disseminate educational materials fo-
cused on infection prevention and control for use in health 
care facilities across the continuum of care and in commu-
nity settings.’’. 
SEC. 4. PROTECTION OF CONFIDENTIAL AND NATIONAL SE-
CURITY INFORMATION. 
This Act, and the amendments made by this Act, 
shall not be construed to permit the disclosure of any 
trade secret, confidential commercial information, or ma-
terial inconsistent with national security, that is otherwise 
prohibited by law. 
Æ 
VerDate Sep 11 2014 
02:59 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6301
E:\BILLS\H9094.IH
H9094
kjohnson on DSK79L0C42PROD with BILLS